Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC-Reference-Cited by-同舟云学术

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Published:2020-10-01 Issue:14 Volume:383 Page:1328-1339
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Herbst Roy S.¹,Giaccone Giuseppe¹,de Marinis Filippo¹,Reinmuth Niels¹,Vergnenegre Alain¹,Barrios Carlos H.¹,Morise Masahiro¹,Felip Enriqueta¹,Andric Zoran¹,Geater Sarayut¹,Özgüroğlu Mustafa¹,Zou Wei¹,Sandler Alan¹,Enquist Ida¹,Komatsubara Kimberly¹,Deng Yu¹,Kuriki Hiroshi¹,Wen Xiaohui¹,McCleland Mark¹,Mocci Simonetta¹,Jassem Jacek¹,Spigel David R.¹

Affiliation:

1. From the Yale School of Medicine, New Haven, CT (R.S.H.); Weill Cornell Medical Center, New York (G.G.); the European Institute of Oncology, IRCCS, Milan (F.M.); Asklepios Lung Clinic, Munich-Gauting, Germany (N.R.); University Hospital Limoges, Limoges, France (A.V.); Centro de Pesquisa Clínica, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); Nagoya University Graduate School of Medicine, Aichi, Japan (M. Morise); Vall d’Hebron University...

Funder

F. Hoffmann-La Roche

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1917346

Cited by 905 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma cell-free RNA PD-L1 or tissue PD-L1 protein expression and outcomes with first-line immunotherapy in metastatic non-small cell lung cancer;The Journal of Liquid Biopsy;2024-03

2. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study;European Journal of Cancer;2024-03

3. Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-03

4. Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis;ACS Nano;2024-02-06

5. Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States;Frontiers in Pharmacology;2024-02-05